More than a million patients in Europe suffer from one of the 12 most recognized rare diseases, which can all be treated with plasma-derived therapies (PDTs).1 Treatment with PDTs can significantly improve the quality of life and life expectancy of people with a rare disease. However, the availability of these valuable therapies depends entirely on human plasma donated by healthy individuals.
Global demand for plasma and these vital therapies continues to exceed supply. Source plasma donation is limited to very few countries, due to restrictive regulations and policies that are largely based on outdated science. Geographic imbalance and over-reliance on plasma donated in the U.S. place peoples’ lives at risk. Like much of the world, Europe relies heavily on imported plasma, and there is a strong case for considering ways to update regulation and increase opportunity for plasma collection there.
A new report by one of the leading independent economic firms in Europe, Copenhagen Economics, explores the value of PDTs for patients and of the plasma industry to the wider European economy, as well as the challenges associated with meeting rapidly growing demand for plasma. Commissioned by Takeda, the report, “The impact of plasma-derived therapies in Europe,” offers holistic yet innovative solutions to help ensure improved and sustainable patient access to safe and efficacious PDTs in Europe and across the world.
1 Jervelund, C., Haanperä, T., Siersbæk, N., The Impact Of Plasma-Derived Therapies In Europe. Copenhagen Economics. June 2021; 1-82